Imiquimod + Pembrolizumab for Skin Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial studies the effects of combining imiquimod and pembrolizumab to treat advanced melanoma. Imiquimod boosts the immune system, and pembrolizumab helps the immune system attack cancer cells. Pembrolizumab is a standard treatment for advanced melanoma, and imiquimod has shown promise in treating melanoma metastases. The goal is to see if this combination works better than current treatments.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that you should not have received certain cancer treatments recently, and you should not have active infections or uncontrolled illnesses. It's best to discuss your current medications with the trial team to be sure.
Is the combination of Imiquimod and Pembrolizumab safe for treating skin cancer?
How is the drug combination of Imiquimod and Pembrolizumab unique for treating skin cancer?
This treatment is unique because it combines Imiquimod, a topical cream that boosts the immune response to fight skin cancer, with Pembrolizumab, an injectable drug that helps the immune system attack cancer cells by blocking a pathway that tumors use to hide from immune cells. This combination leverages both local and systemic immune activation, offering a novel approach compared to traditional treatments like surgery or single-drug therapies.16789
What data supports the effectiveness of the drug Pembrolizumab for skin cancer?
Pembrolizumab has shown strong antitumor activity in skin cancer, specifically in recurrent/metastatic cutaneous squamous cell carcinoma, with meaningful and lasting effects. It has also been effective in treating melanoma, another type of skin cancer, with high response rates and low toxicity.16101112
Who Is on the Research Team?
Ruqin Chen, MD, MB
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This trial is for patients with stage IIIB-IV melanoma who haven't had pembrolizumab or similar therapies for metastatic disease. They must have a treatable skin lesion, confirmed diagnosis not suitable for surgery, good performance status and lab values, no severe diseases that could interfere with the trial, no active infections or certain heart conditions, and be willing to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive pembrolizumab IV on day 1 and apply imiquimod cutaneously on days 1-5, with cycles repeating every 21 days for up to 2 years
Follow-up
Participants are monitored for safety and effectiveness after treatment completion
What Are the Treatments Tested in This Trial?
Interventions
- Imiquimod
- Pembrolizumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
National Cancer Institute (NCI)
Collaborator